pJAK2(1001-1013) 

pJAK2(1001-1013) is a cell-penetrating peptide that corresponds to the activation loop of JAK2 tyrosine kinase and functions as a SOCS1/3antagonist. pJAK2 (1001-1013) blocks SOCS1-mediated negative regulation of immune function, and enhances the biological activity of cytokines such as IFNγ and IL6. pJAK2(1001-1013) inhibits the replication of a broad range of viruses and exerts dose-dependent protective efficacy against lethal viral infections. pJAK2(1001-1013) can be used for the study of immune regulation and infection^[1][2][3].

pJAK2 (1001-1013) (50 μM) inhibits vaccinia virus replication by approximately 92% (intracellular virus yield) and 83% (extracellular virus yield)^[1].
pJAK2 (1001-1013) (24 μM) inhibits EMCV growth by approximately 50%^[1].
pJAK2(1001-1013) (11 μM, 22 h pretreatment) enhances the antiviral activity of suboptimal IFN-γ against encephalomyocarditis virus (EMCV) in human fibroblast WISH cells^[2].
pJAK2(1001-1013) (20 μM, 30 min treatment) reverses SOCS-1-induced inhibition of IL-6-mediated STAT3 phosphorylation in SOCS-1-transfected human prostate cancer LNCaP cells^[2].
pJAK2(1001-1013) (1-5 μM, 48 h) enhances IFN-γ-induced GAS promoter activity in WISH cells (transfected with pGAS-Luc reporter plasmid)^[2].
pJAK2(1001-1013) (18 h pretreatment) inhibits replication of influenza A virus PR8 strain in MDCK cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

pJAK2(1001-1013) (10-200 μg, i.p., once per day) demonstrates dose-dependent protective efficacy against lethal intranasal vaccinia virus or encephalomyocarditis virus (EMCV) infection in C57BL/6 mice^[1].
pJAK2(1001–1013) (200 μg/mouse, i.p., on day -2, -1, and 0 relative to BSA immunization) enhances the Ag-specific immune response in C57BL/6 mice^[2].
pJAK2(1001-1013) (200 μg/mouse, i.p., once daily for 1 week) demonstrates protective efficacy against lethal infection with influenza A/PR8 virus in female C57BL/6 mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1716.82

C₇₆H₁₁₈N₁₇O₂₆P

1259928-08-9

Solid

White to off-white

Leu-Pro-Gln-Asp-Lys-Glu-{pTyr}-Tyr-Lys-Val-Lys-Glu-Pro

LPQDKE-{pTyr}-YKVKEP

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Ahmed CM, et al. SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function. Front Immunol. 2015 Apr 21;6:183.  [Content Brief]

  [2]. Waiboci LW, et al. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J Immunol. 2007 Apr 15;178(8):5058-68.  [Content Brief]

  [3]. Ahmed CM, et al. A SOCS1/3 Antagonist Peptide Protects Mice Against Lethal Infection with Influenza A Virus. Front Immunol. 2015 Nov 11;6:574.  [Content Brief]